Adenosine A2a receptor antagonists

US6653315B2 · kind B2 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Deen Tulshian · Lebanon, US
• Lisa S. Silverman · Edison, US
• Julius J. Matasi · Monmouth Junction, US
• Eugenia Y. Kiselgof · Flemington, US
• John P. Caldwell · Ringwood, US

Key dates

• Filing date: Oct 11, 2002
• Grant date: Nov 25, 2003
• Expiry date: Oct 11, 2022

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02P20/582
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, whereinR is optionally substituted phenyl or heteroaryl, cycloalkenyl, —C(═CH2)CH3, —C≡C—CH3, —CH═C(CH3)2, X is alkylene, —C(O)CH2— or —C(O)N(R2)CH2—;Y is —N(R2)CH2CH2N(R3)—, —OCH2CH2N(R2)—, —O—, —S—, —CH2S—, —(CH2)2—N(R2)—, or optionally substituted divalent heteroaryl, piperidinyl or piperazinyl; andZ is optionally substituted phenyl, phenylalkyl or heteroaryl, diphenylmethyl or R6—C(O)—;or when Y is Z is also R6—SO2—, R7—N(R8)—C(O)—, R7—N(R8)—C(S)— or R6OC(O)—;or when Y is 4-piperidinyl, Z can be phenylamino or pyridylamino; orZ and Y together are substituted piperidinyl, substituted pyrrolidinyl or substituted phenyl;R14 is H, halogen or optionally substituted alkyl; andQ, Q1, m, n, R2, R3, R4, R6, R7 and R8 are as defined in the specification are disclosed, their use in the treatment of Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and…